EX-10.1
from 10-Q
2 pages
Xenogen Corporation, With a Principal Place of Business at 860 Atlantic Avenue, Alameda, Ca 94501 (“Xenogen”) and Biosynth International, Inc., With a Principal Place of Business at 1665 West Quincy Avenue, Suite 155, Naperville, Il 60540 (“Biosynth”), (Each a “Party” and Collectively, the “Parties”), Hereby Amend That Certain D-Luciferin Supply Agreement, Dated December 31, 2001, by and Between the Parties Hereto (The “Agreement”), Effective as of April , 2004 (The “Amendment Date”)
12/34/56